Get the Stockscreener App
106.28
1.96%
-2.13
Sarepta Therapeutics Inc stock is traded at $106.28, with a volume of 642.29K.
It is down -1.96% in the last 24 hours and down -9.00% over the past month.
See More
Previous Close:
$108.41
Open:
$109.5
24h Volume:
642.29K
Relative Volume:
0.75
Market Cap:
$11.66B
Revenue:
$1.64B
Net Income/Loss:
$121.85M
P/E Ratio:
69.01
EPS:
1.54
Net Cash Flow:
$-480.40M
1W Performance:
-1.55%
1M Performance:
-9.00%
6M Performance:
-25.91%
1Y Performance:
-19.66%
1-Day Range:
$106.02
$110.00
1-Week Range:
$101.15
$110.00
52-Week Range:
$101.15
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
106.28 | 11.66B | 1.64B | 121.85M | -480.40M | 1.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics (SRPT) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
Rhumbline Advisers Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
AlphaCentric Advisors LLC Lowers Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now? - Insider Monkey
15 Best Fast Growth Stocks To Buy Right Now - Insider Monkey
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week LowHere's Why - MarketBeat
Van ECK Associates Corp Raises Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here? - Benzinga
Sarepta Therapeutics Closes $600M in Senior Secured Revolving Credit Facility - citybiz
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Peregrine Capital Management LLC - MarketBeat
Allspring Global Investments Holdings LLC Acquires 84,926 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock - MSN
SRPT Quantitative Stock Analysis - Nasdaq
Solid says early data suggest ‘differentiated’ Duchenne gene therapy - BioPharma Dive
Sarepta stock touches 52-week low at $101.32 amid market challenges - Investing.com
Braun Stacey Associates Inc. Sells 2,990 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround - MSN
Banque Pictet & Cie SA Has $5.35 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Fiera Capital Corp Sells 9,667 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
Sarepta closes on $600M revolving credit facility - MSN
Sovran Advisors LLC Invests $3.21 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics closes on $600M credit facility - TradingPedia
Sapient Capital LLC Cuts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
WCM Investment Management LLC Buys 12,060 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility - Marketscreener.com
Sarepta Therapeutics Closes $600 Million Revolving Credit Facility -February 14, 2025 at 09:08 am EST - Marketscreener.com
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Sarepta Q4 Earnings Preview: Rare Disease Leader's Full-Year Performance Revealed - StockTitan
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Gladstone Institutional Advisory LLC - MarketBeat
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results - Business Wire
Deutsche Bank sets Sarepta stock target at $136, cites risks - MSN
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Hold Rating, $136 Price Target - Marketscreener.com
Tobam Has $3.52 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Arrowhead Secures Massive $825M Deal as FDA Fast-Tracks Breakthrough Drug - StockTitan
Arrowhead Closes Licensing, Collaboration Agreement With Sarepta -February 10, 2025 at 09:39 am EST - Marketscreener.com
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics - BioSpace
Arrowhead to receives $500M upfront in licensing pact with Sarepta - TipRanks
ARWR Seals Mega-Deal: $825M Cash Infusion Plus Billions in Potential Milestone Payments - StockTitan
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):